HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer

被引：0
|
作者：
François Cherifi
Angélique Da Silva
Alison Johnson
Cécile Blanc-Fournier
Olivia Abramovici
Antonin Broyelle
Christelle Levy
Djelila Allouache
Ioana Hrab
Carine Segura
Adeline Morel
Maud Villemin
Clémence Boscher
Coraline Dubot-Poitelon
Pauline Rottier
Justine Lequesne
George Emile
机构：
[1] CLCC Francois Baclesse,Department of Clinical Research
[2] CLCC François Baclesse,Breast Cancer Unit
[3] Institut Normand du Sein,Department of Pathology
[4] CLCC Francois Baclesse,Department of Pathology
[5] CLCC Oscar Lambret,Breast Cancer Unit
[6] CLCC Oscar Lambret,undefined
来源：
BMC Cancer | / 22卷
关键词：
Antibody–drug conjugates; HER2-low; Breast cancer; Trastuzumab–deruxtecan; Neoadjuvant treatment; Lymphocytes; Neutrophils;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Prognostic implications of HER2 changes after neoadjuvant chemotherapy in patients with HER2-zero and HER2-low breast cancer
    Kang, Sora
    Lee, So Heun
    Lee, Hee Jin
    Jeong, Hyehyun
    Jeong, Jae Ho
    Kim, Jeong Eun
    Ahn, Jin-Hee
    Jung, Kyung Hae
    Gong, Gyungyub
    Kim, Hak Hee
    Lee, Saebyeol
    Lee, Jongwon
    Kim, Sung-Bae
    EUROPEAN JOURNAL OF CANCER, 2023, 191
  • [32] Impact of Human Epidermal Growth Factor Receptor 2 (HER2) Low Status in Response to Neoadjuvant Chemotherapy in Early Breast Cancer
    Alves, Fatima R.
    Gil, Lucia
    de Matos, Leonor Vasconcelos
    Baleiras, Ana
    Vasques, Carolina
    Neves, Maria Teresa
    Ferreira, Andre
    Fontes-Sousa, Mario
    Miranda, Helena
    Martins, Ana
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (02)
  • [33] Real-World Data on Pathological Response and Survival Outcomes After Neoadjuvant Chemotherapy in HER2-Low Breast Cancer Patients
    Guan, Dandan
    Shi, Qingyang
    Zheng, Yajuan
    Zheng, Chaopeng
    Meng, Xuli
    CLINICAL BREAST CANCER, 2024, 24 (05) : 463 - 472.e2
  • [34] Impact of HER2-Low Status on Pathologic Complete Response and Survival Outcome Among Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
    Lee, Young Joo
    Yoo, Tae-Kyung
    Lee, Sae Byul
    Chung, Il Yong
    Kim, Hee Jeong
    Ko, Beom Seok
    Lee, Jong Won
    Son, Byung Ho
    Ahn, Sei Hyun
    Jeong, Hyehyun
    Jung, Jae Ho
    Ahn, Jin-Hee
    Jung, Kyung Hae
    Kim, Sung-Bae
    Lee, Hee Jin
    Gong, Gyungyub
    Kim, Jisun
    JOURNAL OF BREAST CANCER, 2025, 28 (01) : 11 - 22
  • [35] Impact of HER2 status (HER2-low versus HER2-0) on complete histologic response after neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC)
    Domergue, C.
    Martin, E.
    Lemarie, C.
    Jezequel, P.
    Frenel, J-S.
    Augereau, P.
    Campone, M.
    Patsouris, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S428 - S429
  • [36] PARP is expressed in all subtypes of early breast cancer and is a predictive factor for response to neoadjuvant chemotherapy
    von Minckwitz, G.
    Mueller, B.
    Loibl, S.
    Blohmer, J. U.
    duBois, A.
    Huober, J.
    Kandolf, R.
    Budczies, J.
    Denkert, C.
    EJC SUPPLEMENTS, 2010, 8 (03): : 188 - 188
  • [37] Prognostic stratification capacity of the CPS plus EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
    Roussot, N.
    Constantin, G.
    Desmoulins, I.
    Kaderbhai, C.
    Hennequin, A.
    Mayeur, D.
    Ilie, S. M.
    Arnould, L.
    Bertaut, A.
    Eymard, J-C.
    Jouannaud, C.
    Savoye, A. M.
    Yazbek, G.
    Allouache, D.
    Delcambre, C.
    Hrab, I.
    Levy, C.
    Djezzer, C. Segura
    Deblock, M.
    Ladoire, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S285 - S285
  • [38] Prognostic stratification ability of the CPS plus EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
    Roussot, Nicolas
    Constantin, Guillaume
    Desmoulins, Isabelle
    Bergeron, Anthony
    Arnould, Laurent
    Beltjens, Francoise
    Mayeur, Didier
    Kaderbhai, Coureche
    Hennequin, Audrey
    Jankowski, Clementine
    Padeano, Marie Martine
    Costaz, Helene
    Jacinto, Sarah
    Michel, Eloise
    Amet, Alix
    Coutant, Charles
    Costa, Brigitte
    Jouannaud, Christelle
    Deblock, Mathilde
    Levy, Christelle
    Ferrero, Jean -Marc.
    Kerbrat, Pierre
    Brain, Etienne
    Mouret-Reynier, Marie-Ange
    Coudert, Bruno
    Bertaut, Aurelie
    Ladoire, Sylvain
    EUROPEAN JOURNAL OF CANCER, 2024, 202
  • [39] Favorable effect of HER2-low expression on prognosis for breast cancers after neoadjuvant chemotherapy
    Zhao, Yingying
    Yin, Wenjin
    Chen, Xinru
    Lu, Jingsong
    CANCER RESEARCH, 2024, 84 (09)
  • [40] Event-free survival in HER2-low vs HER2-zero breast cancer patients submitted to neoadjuvant chemotherapy
    Sartori, Guilherme
    Ramalho, Susana
    da Silva, Leonardo Roberto
    Reinert, Tomas
    Da Rosa, Mahira Lopes
    Tavares, Grazielle Morais
    Vasconcelos, Vivian
    Mantovani, Higor
    Cabello, Ana Elisa Ribeiro Da Silva
    Coelho, Guilherme
    Mandelli, Jovana
    Zaffaroni, Facundo
    Cabello, Cesar
    Barrios, Carlos
    Graudenz, Marcia Silveira
    CANCER RESEARCH, 2024, 84 (09)
12345